Adults who used a glucagon-like peptide receptor agonist for weight loss and had asthma experienced improved asthma control, according to a poster presented at the European Respiratory Society International Congress.
“Although designed predominantly for weight loss, it seems that GLP-1s will have widespread benefits on comorbidities relating to obesity, including asthma,” Heath Heatley, PhD, senior researcher at Observational and Pragmatic Research Institute, said during his presentation. “Quantifying these associations will be useful in considering the health economic